Immunotherapy: New insights in breast cancer treatment

Article type: Review Article

Authors: Alshehri, Bader

Affiliations: Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Almajmaah-11952, Kingdom of Saudi Arabia | Tel.: +966 544258083; E-mail: baderalshehricams@gmail.com, b.alshehri@mu.edu.sa

Abstract: Breast cancer being the most malignant and lethal disease persistent among women globally. Immunotherapy as a new treatment modality has emerged in understanding the loopholes in the treatment of breast cancer which is mainly attributed to the potential of tumor cells to evade and survive the immune response by developing various strategies. Therefore, improved understanding of the immune evasion by cancer cells and the monoclonal antibodies against PD- and PD-L1 can help us in the diagnosis of this malignancy. Here in this article, I have highlighted that in addition to focusing on other strategies for breast cancer treatment, the involvement of immune system in breast cancer is vital for the understanding of this malignancy. Further, the complete involvement of immune system in the relapse or recurrence of the breast tumor and have also highlighted the role of vaccines, PD-1 and CTLA-4 with the recent advances in the field. Moreover, in addition to the application of immunotherapy as a sole therapy, combinations of immunotherapy with various strategies like targeting it with MEK inhibitors, Vaccines, chemotherapy and PARP inhibitor has shown to have significant benefits is also discussed in this article.

Keywords: Breast cancer, immunotherapy, PARP inhibitor, vaccines, PD-1, PD-L1, CTLA-4

DOI: 10.3233/HAB-210443

Journal: Human Antibodies, vol. 29, no. 3, pp. 193-202, 2021